Administration of teclistamab in four patients with multiple myeloma requiring hemodialysis

Khouderchah, Christy J
Ochs, Madeleine
Pianko, Matthew
Mahmoudjafari, Zahra
Snyder, Jordan
Ahmed, Iman
Campagnaro, Erica
Nachar, Victoria R

¹Department of Pharmacy Services and Clinical Pharmacy, 21614Michigan Medicine, Ann Arbor, MI, USA
²University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA
³Division of Hematology/Oncology, Department of Internal Medicine, 12266University of Michigan Medical School, Ann Arbor, MI, USA
⁴Department of Pharmacy, 145762University of Kansas Cancer Center, Kansas City, KS, USA

Victoria R Nachar, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA. Email: [email protected]

Received November 30, 2023

Received in revised form March 9, 2024

Accepted March 10, 2024

Journal of Oncology Pharmacy Practice 30(6):p 1089-1095, September 2024. | DOI: 10.1177/10781552241242022

Objective

Relapsed/refractory multiple myeloma (MM) has poor outcomes, especially in heavily pretreated patients. Limited data exists on the use of novel therapies in MM patients with renal dysfunction. This case series describes the successful initiation of teclistamab in four patients with heavily pre-treated MM on hemodialysis (HD).

Data Sources

The medical records of four adult MM patients on HD who received teclistamab were retrospectively reviewed.

Data Summary

All patients completed teclistamab step-up dosing and received at least one full dose. HD runs were administered irrespective of teclistamab initiation. Patients tolerated therapy well, with only one patient experiencing grade 1 CRS, which was managed with supportive care.

Conclusions

Due to the complexity of this patient population, close monitoring and multidisciplinary care are crucial. This approach is essential for effectively managing MM patients with renal dysfunction and for exploring novel treatment options.